Mitchell Elkind, MD, MS is a tenured Professor of Neurology and Epidemiology at Columbia University, and Chief of the Division of Neurology Clinical Outcomes Research and Population Sciences (Neuro CORPS) in the Neurology Department. Dr. Elkind received his medical degree from Harvard Medical School. He trained in Internal Medicine at Brigham and Women’s Hospital and in Neurology at Massachusetts General Hospital, both in Boston, MA. He completed a fellowship in Vascular Neurology and Neuroepidemiology at Columbia University Medical Center. Dr. Elkind holds a Master’s degree in Epidemiology from Columbia’s Mailman School of Public Health. Dr Elkind’s research focuses on stroke prevention, inflammatory and infectious biomarkers in stroke risk prediction, atrial cardiopathy, immune therapy for acute stroke, and vascular causes of cognitive aging. Dr. Elkind is the Principal Investigator of several independent investigator awards from NIH/NINDS, including the ARCADIA trial of apixaban vs aspirin for atrial cardiopathy in cryptogenic stroke and the Northern Manhattan Study (NOMAS), an epidemiological study of stroke risk factors. He is President-Elect of the American Heart Association.